Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA, BIO Alliance Promotes Industry Agenda On Comparative Effectiveness

Executive Summary

The Pharmaceutical Research and Manufacturers of America, the Biotechnology Industry Organization and the Advanced Medical Technology Association have formed a coalition to promote an industry agenda on comparative clinical effectiveness

You may also be interested in...



Baucus Wants To Keep Comparative Effectiveness Separate From Cost Control

One of the first skirmishes in the 2009 health care reform debate is likely to occur over comparative effectiveness

Baucus Wants To Keep Comparative Effectiveness Separate From Cost Control

One of the first skirmishes in the 2009 health care reform debate is likely to occur over comparative effectiveness

Drug Price Versus Value: British Pharma Plans Public Debate In November

Having called for a public debate on how the United Kingdom values and provides access to new medicines, the Association of the British Pharmaceutical Industry is organizing to make it happen

Related Content

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel